BiotechTube

DRL-17822 or placebo

Phase 2Completed
3 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type II Hyperlipidemia

Conditions

Type II Hyperlipidemia

Trial Timeline

Jul 1, 2011 → Jun 1, 2012

NCT ID
NCT01388816

About DRL-17822 or placebo

DRL-17822 or placebo is a phase 2 stage product being developed by Dr. Reddy's Laboratories for Type II Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01388816. Target conditions include Type II Hyperlipidemia.

What happened to similar drugs?

20 of 20 similar drugs in Type II Hyperlipidemia were approved

Approved (20) Terminated (0) Active (0)
✅add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
✅Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
✅Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
✅exenatide and sitagliptin + exenatide and placeboEli LillyApproved
✅Tirzepatide + PlaceboEli LillyApproved
✅LisproEli LillyApproved
✅ToujeoMIRA PharmaceuticalsApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01388816Phase 2Completed

Competing Products

20 competing products in Type II Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
NEX-22A, a prolonged release formulation of liraglutideNanexa ABPhase 1
23
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
29
MKP10241 + PlaceboMankind PharmaPhase 2
42
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
21
LY3209590 + Insulin DegludecEli LillyPhase 1
29
AC2993Eli LillyPhase 3
40
LY3209590 + PlaceboEli LillyPhase 1
29
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
40
LY2963016 + LantusEli LillyPhase 1
29
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
26
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
43
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
40
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
26
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
36
Placebo + LinagliptinEli LillyPhase 3
40
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
43
teplizumab or placeboEli LillyPhase 1
21
LY2428757 + PlaceboEli LillyPhase 2
35
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
40